On March 19, 2020,
the Board of Directors (the Board) of Corvus Pharmaceuticals, Inc. (Corvus or the Company),
approved, on recommendation of the Compensation Committee of the Board, stock option awards for all of the Companys directors,
excluding Richard A. Miller, M.D. The stock option awards to each of the directors were granted effective as of the close of business
on March 19, 2020 with an exercise price equal to the closing price of the Companys common stock as reported on The Nasdaq
Global Market on the date of grant. The awards were made pursuant to the Companys 2016 Equity Incentive Award Plan and will
vest on the one year anniversary of the date of the grant, subject to continued service as of the vesting date.
sets forth the number of shares underlying the stock option awards for each of the directors:
Name of Director
Stock Option Award
Ian T. Clark
Elisha P. (Terry) Gould III
Linda S. Grais, M.D., J.D.
Steve E. Krognes
Scott W. Morrison
Peter Thompson, M.D.
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
CORVUS PHARMACEUTICALS, INC.
Date: March 20, 2020
/s/ Leiv Lea
Chief Financial Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
On September - Sept. 17, 2020
Corvus Pharmaceuticals, Inc. director was just granted 30,000 options - Sept. 15, 2020
Corvus Pharmaceuticals, Inc. director just declared 0 ownership of the company. - Sept. 15, 2020
Departure of Directors or Certain - Sept. 11, 2020
On September - Sept. 10, 2020